Avian oncolytic virus having modified sequences and uses thereof
AssigneeARV Pharma Inc.
InventorsRobert Kozak, Byram Bridle, Eva Nagy, Bradley Thompson
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to one or more modified avian-virus based agents, therapies, treatments, and methods of use of the modified avian-virus based agents and/or therapies and/or treatments for cancer. The disclosure also provides for methods of generating modified avian-virus based agents.
Claims5
An oncolytic agent comprising a modified avian-virus that has an increased oncolytic activity as compared to a non-avian, oncolytic-virus based agent from the same group, wherein the modified avian virus is an avian reovirus with a nucleotide sequence that comprises SEQ NO. 1, SEQ NO. 2, SEQ NO. 3, SEQ NO. 4, SEQ NO. 5, SEQ NO. 6, SEQ NO. 7, SEQ NO. 8, SEQ NO. 9 and SEQ NO. 10.
A method of making an agent/target cell complex, the method comprising a step of administering a therapeutically effective amount of an oncolytic agent to a subject, wherein the oncolytic agent comprises a modified avian virus that has an increased oncolytic activity as compared to an non-avian oncolytic virus-agent from the same group, and wherein the target cell is a cancer cell and wherein the modified avian virus is an avian reovirus with a nucleotide sequence that comprises SEQ NO. 1, SEQ NO. 2, SEQ NO. 3, SEQ NO. 4, SEQ NO. 5, SEQ NO. 6, SEQ NO. 7, SEQ NO. 8, SEQ NO. 9 and SEQ NO. 10.
Dependencies are inferred from the claim text.